Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company specializing in next-generation cancer therapies, has announced its participation in the upcoming MedInvest Biotech and Pharma Investor Conference. The event will take place on March 27-28, 2025, at Cooley's law office in New York City.
The company's management team will deliver a corporate overview presentation on March 28th at 9:40 a.m. Eastern time. Additionally, they will engage in one-on-one meetings with registered investors and conference attendees throughout the event. The presentation materials will be made accessible on Processa's website.
Processa Pharmaceuticals (Nasdaq: PCSA), un'azienda farmaceutica in fase clinica specializzata in terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione alla prossima MedInvest Biotech and Pharma Investor Conference. L'evento si svolgerà il 27 e 28 marzo 2025 presso lo studio legale Cooley a New York City.
Il team di gestione dell'azienda presenterà una panoramica aziendale il 28 marzo alle 9:40 ora orientale. Inoltre, parteciperanno a incontri individuali con investitori registrati e partecipanti alla conferenza durante tutto l'evento. I materiali della presentazione saranno resi disponibili sul sito web di Processa.
Processa Pharmaceuticals (Nasdaq: PCSA), una empresa farmacéutica en etapa clínica especializada en terapias oncológicas de nueva generación, ha anunciado su participación en la próxima MedInvest Biotech and Pharma Investor Conference. El evento se llevará a cabo el 27 y 28 de marzo de 2025 en la oficina legal Cooley en la ciudad de Nueva York.
El equipo de gestión de la empresa ofrecerá una presentación general corporativa el 28 de marzo a las 9:40 a.m. hora del este. Además, participarán en reuniones uno a uno con inversores registrados y asistentes a la conferencia durante todo el evento. Los materiales de la presentación estarán disponibles en el sitio web de Processa.
Processa Pharmaceuticals (Nasdaq: PCSA), 차세대 암 치료제에 전문화된 임상 단계 제약 회사가 다가오는 MedInvest Biotech and Pharma Investor Conference에 참여한다고 발표했습니다. 이 행사는 2025년 3월 27일부터 28일까지 뉴욕시의 Cooley 법률 사무소에서 열릴 예정입니다.
회사의 경영진 팀은 3월 28일 오전 9시 40분 동부 표준시에 기업 개요 발표를 진행할 것입니다. 또한, 행사 기간 동안 등록된 투자자 및 참석자들과 일대일 미팅을 진행할 예정입니다. 발표 자료는 Processa의 웹사이트에서 확인할 수 있습니다.
Processa Pharmaceuticals (Nasdaq: PCSA), une entreprise pharmaceutique en phase clinique spécialisée dans les thérapies anticancéreuses de nouvelle génération, a annoncé sa participation à la prochaine MedInvest Biotech and Pharma Investor Conference. L'événement se déroulera les 27 et 28 mars 2025 au cabinet d'avocats Cooley à New York.
La direction de l'entreprise présentera un aperçu de l'entreprise le 28 mars à 9h40, heure de l'Est. De plus, ils participeront à des réunions individuelles avec des investisseurs enregistrés et des participants à la conférence tout au long de l'événement. Les documents de présentation seront accessibles sur le site Web de Processa.
Processa Pharmaceuticals (Nasdaq: PCSA), ein klinisches Pharmaunternehmen, das sich auf innovative Krebstherapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden MedInvest Biotech and Pharma Investor Conference bekannt gegeben. Die Veranstaltung findet am 27. und 28. März 2025 in der Kanzlei Cooley in New York City statt.
Das Management-Team des Unternehmens wird am 28. März um 9:40 Uhr Eastern Time eine Unternehmenspräsentation halten. Darüber hinaus werden sie während der gesamten Veranstaltung Einzelgespräche mit registrierten Investoren und Konferenzteilnehmern führen. Die Präsentationsunterlagen werden auf der Website von Processa verfügbar sein.
- None.
- None.
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley’s law office in New York City.
Management will present a corporate overview on Friday, March 28th at 9:40 a.m. Eastern time, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. The presentation will be available on Processa’s website.
For more information about the MedInvest Biotech and Pharma Investor Conference, please click here.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
# # #
FAQ
When and where is Processa Pharmaceuticals (PCSA) presenting at the MedInvest Conference?
What type of meetings will PCSA management conduct at the MedInvest Conference?
Where can investors access Processa's MedInvest Conference presentation materials?
What is Processa Pharmaceuticals' (PCSA) current development focus?
